A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment

Journal of Korean Medical Science

Volumn 28, Issue 12, 2013, Pages 1716-1722

  Kim, Jinhyun ^a   Ryu, Heejung ^b   Yoo, Dae Hyun ^c   Park, Sung Hwan ^d   Song, Gwan Gyu ^e   Park, Won ^f   Cho, Chul Soo ^d   Song, Yeong Wook ^a  

^a Seoul National University Hospital   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f Inha University School of Medicine   (South Korea)

Author keywords

Adverse event; Arthritis, rheumatoid; Efficacy; Extension study; Infliximab; Placebo controlled clinical trial

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY;

ADULT; ADVERSE EVENT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; EFFICACY; EXTENSION STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PLACEBO EFFECT; PLACEBO-CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; TIME; TREATMENT OUTCOME;

ADVERSE EVENT; ARTHRITIS, RHEUMATOID; EFFICACY; EXTENSION STUDY; INFLIXIMAB; PLACEBO-CONTROLLED CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PLACEBO EFFECT; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906527962     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.12.1716     Document Type: Article

References (19)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, Buchan G, Barrett K, Barkley D, Chu A. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 1990; 49: 480-6.
3. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-9.
4. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
5. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
6. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group. Lancet 1999; 354: 1932-9.
7. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
8. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007; 17: 28-32.
9. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 2008; 18: 146-52.
10. Gao GH, Li J, Xie HW, Lü Z. Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 724-6.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
12. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502.
13. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo: the Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990; 33: 477-84.
14. Uppsala Monitoring Centre. The WHO adverse reaction terminology - WHO-ART. Available at http://www.umc-products.com/graphics/3149.pdf [accessed on 3 January 2012].
15. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther 2011; 13: S2.
16. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005; 118: 515-20.
17. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
18. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
19. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rah-man MU; START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1075-86.